Analysts at SVB Leerink downgraded shares of Moderna Inc. MRNA, -3.45% to underperform from market perform, citing growing "competitive pressure" from other developers of COVID-19 vaccines. Shares of Moderna were down 7.3% in premarket trading on Tuesday. The analysts said it's still likely that the Moderna's coronavirus vaccine candidate will be authorized by the Food and Drug Administration in the fourth quarter of this year "but speed to market has fallen behind competitors." Unlike other drugmakers developing experimental COVID-19 vaccines, such as Johnson & Johnson JNJ, -0.64% and Pfizer Inc. PFE, -0.11%, Moderna does not have any other approved products to buffer the company's revenue-earning potential. Moderna's stock has soared 220.0% so far this year, while the S&P 500 SPX, -0.81% has gained 6.0%.
Reprinted from marketwatch, the copyright all reserved by the original author.
風險提示：本文所述僅代表作者個人觀點，不代表 Followme 的官方立場。Followme 不對內容的準確性、完整性或可靠性作出任何保證，對於基於該內容所採取的任何行為，不承擔任何責任，除非另有書面明確說明。
暫無評論，立馬搶沙發